Need assistance? We're here to help with support, guidance, and resources. Reach out to us anytime.
The AI-Powered ICU Antimicrobial Stewardship (AMS) and Antimicrobial Resistance (AMR) Management Platform is an advanced clinical decision support solution designed to help hospitals combat the growing threat of antimicrobial resistance while improving patient outcomes in critical care environments.
Built on a scalable AI and healthcare data platform, the solution integrates with hospital information systems, Electronic Medical Records (EMR), Laboratory Information Systems (LIS), pharmacy systems, microbiology databases, ICU monitoring devices, and clinical workflows to deliver real-time intelligence for antibiotic prescribing and antimicrobial stewardship.
The platform continuously analyzes patient vitals, laboratory results, microbiology reports, medication history, prior culture data, comorbidities, and treatment pathways to predict antimicrobial resistance risks, recommend evidence-based antibiotic therapies, automate stewardship monitoring, and generate compliance-ready audit reports.
The solution supports hospital AMS committees, infectious disease specialists, intensivists, microbiologists, pharmacists, and quality teams by enabling data-driven decision-making while aligning with international and national guidelines including Infectious Diseases Society of America (IDSA), Indian Council of Medical Research (ICMR), Clinical and Laboratory Standards Institute (CLSI) and National Accreditation Board for Hospitals & Healthcare Providers (NABH) requirements.
Hospitals face increasing prevalence of multidrug-resistant organisms (MDROs), resulting in prolonged hospital stays, increased mortality, and higher treatment costs.
Clinicians often lack predictive tools to identify patients likely to develop resistant infections before culture results become available.
Empirical broad-spectrum antibiotic use remains common, leading to antimicrobial overuse and accelerating resistance development.
Patient information is dispersed across EMR, laboratory, pharmacy, ICU monitoring systems, and microbiology databases, limiting timely clinical decision-making.
AMS teams spend significant time collecting, validating, and reporting antimicrobial usage metrics for compliance and quality reviews.
Most hospitals rely on retrospective analyses rather than continuous monitoring of resistance patterns and stewardship performance.
The key solution consists of Real-Time AMR Prediction engine, Antibiotics recommendations engine, automated anti-biograms and intelligent alerts, AMS audit and compliance dashboard etc. System takes inputs from multiple hospital systems and acts like a clinical decision support system for critical care professionals.
We harness the capabilities of artificial intelligence to drive innovation, streamline processes, and create smarter business solutions. Our approach focuses on blending cutting-edge AI technologies.
It is a clinical decision support platform that uses AI and machine learning to predict antimicrobial resistance risks, recommend optimal antibiotic therapies, automate stewardship activities, and improve ICU patient outcomes.
The engine continuously analyzes patient vitals, laboratory results, microbiology history, prior cultures, and antibiotic exposure to identify patients at high risk for multidrug-resistant infections.
Yes. The system generates evidence-based antibiotic recommendations, including drug selection, dosage, duration, and de-escalation guidance based on patient-specific factors and clinical guidelines.
The recommendation engine aligns with IDSA, ICMR, CLSI, institutional antimicrobial stewardship policies, and local resistance patterns.
Yes. The platform integrates with EMR, LIS, pharmacy systems, ICU monitoring platforms, microbiology databases, and enterprise healthcare applications using standard healthcare interoperability protocols.
AITCM Group, a upcoming AI & ML Technology startup from India, is founded by Prof Ajay Chhabra, a healthcare digital marketing and Sr. transformation trainer from india. We are building innovative AI solutions that empower businesses, improve lives and have the capabilities to bring substantial positive change in the society and wealth for all stakeholders and investors.
Copyright © 2026 All Rights Reserved.